search
Back to results

Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease

Primary Purpose

Parkinson's Disease

Status
Completed
Phase
Phase 1
Locations
New Zealand
Study Type
Interventional
Intervention
NTCELL
Sponsored by
Living Cell Technologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson's Disease focused on measuring Parkinson's Disease, Xenotransplantation, choroid plexus

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

To be assessed at the Week -10 to -4 Visit

  • Adults (males or females) in the age range 40 to 70 years
  • Diagnosis of Parkinson's disease (minimum duration of 5 years) in accordance with the London Brain Bank criteria
  • Patients diagnosed with idiopathic Parkinson's disease
  • Stable medication for Parkinson's for at least 1 month
  • Patients with advanced and fluctuating Parkinson's disease who have met the criteria for DBS and who have been accepted for DBS at Auckland City Hospital. These criteria include exhaustion of available medication treatments for Parkinson's disease, normal brain MRI, intact cognitive, psychological and psychiatric function, appropriate carer support, and competence and willingness to consent to the placement of deep brain probes
  • If female, no childbearing capability (those who are more than 2 years postmenopausal or have undergone voluntary sterilisation can be considered for enrolment)
  • Provision of written informed consent. Patients will be required to agree to comply with all tests and visits specified in the protocol, and they (and their partners/close contacts) will also be required to consent to long-term microbiological monitoring, which is an integral part of the study.

Exclusion Criteria:

To be assessed at the Week -10 to -4 Visit

Note: the criteria for acceptance for DBS would exclude patients with comorbidities that normally would exclude them from similar studies, including uncontrolled depression, dementia, focal neurological deficits, or secondary parkinsonism. Specific exclusion criteria in this category are:

  • Any history of central nervous system infection
  • Significant dementia as determined by neuropsychological assessment
  • Focal neurological defects
  • Evidence of significant medical or psychiatric disorders
  • Secondary parkinsonism
  • Severe autonomic symptoms
  • Atypical Parkinson's disease
  • History of substance abuse
  • Body mass index (BMI) ≥30 kg/m2 or ≤20 kg/m2

  • Serious comorbid conditions that are likely to affect participation in the study, including:

    • Previous coronary heart disease manifesting as non-ST elevation myocardial infarction (NSTEMI), Q-wave infarction or unstable angina; coronary artery bypass graft (CABG); or percutaneous angioplasty
    • Previous cerebrovascular disease manifesting as transient ischaemic attacks (TIAs) or stroke
    • Peripheral vascular disease with foot ulcer and/or previous amputation
    • History of New York Heart Association (NYHA) class II, III or IV congestive heart failure (CHF) and/or chronic atrial fibrillation
    • Chronic obstructive pulmonary disease (COPD) or asthma with previous hospitalisation for decompensation; a requirement for mechanical ventilation at any stage; or long-term treatment with oral corticosteroids
    • Liver disease with abnormal liver function tests defined as serum bilirubin ≥20 µmol/L, and/or ALT ≥100 U/L, and/or GGT ≥100 U/L, and/or albumin < 35 g/L
    • Haematological disorders, including haemoglobin ≤110 g/L or platelet count < 80 x 109/L
    • Kidney disease, defined as serum creatinine > 130 μmol/L in men and > 110 μmol/L in women and/or haematuria and/or active urinary sediment or casts
    • Peptic ulcer disease and/or history of previous gastrointestinal bleeding
    • Malignancy other than basal cell carcinoma
    • History of epilepsy
    • Untreated hypothyroidism
    • Known adrenal insufficiency

Other exclusion criteria:

  • Past history of brain surgery for Parkinson's disease
  • Poor candidate for any surgery
  • HIV antibody and/or risk factors for HIV infection
  • Positive hepatitis C antibody, positive hepatitis B surface antigen, and hepatitis B core antibody
  • Current administration of immunosuppressive medications (e.g. cyclosporin, tacrolimus, sirolimus, mycophenolate mofetil, muromonab-CD3, daclizumab, basiliximab, antithymocyte globulin, interferons) for other disease conditions
  • Inability to travel on aeroplane to Vancouver (for PET scan)
  • Any other condition that, in the opinion of the Investigator, may interfere with adherence to the study protocol.

Sites / Locations

  • Auckland City Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NTCELL

Arm Description

NTCELL 40 microcapsules (+/- 20%) The NTCELL microcapsules are drawn up into a catheter system and introduced intracranially by stereotactic insertion into the brain under guidance by neuroimaging.

Outcomes

Primary Outcome Measures

the safety of xenotransplantation of NTCELL
measured by the incidence of adverse events, clinical laboratory tests (including xenogeneic viral analysis), physical examination, review by infectious disease physician

Secondary Outcome Measures

Brain metabolism as demonstrated on PET with [18F]-fluorodopa measured at 26 weeks post-implant 1 compared with baseline
Brain metabolism as demonstrated on PET with [11C]-tetrabenazine measured at 26 weeks post-implant 1 compared with baseline
Scores measured by the Unified Parkinson's Disease Rating Scale (UPDRS Parts I, II, III, IV - Parts II and III will be performed in the 'off' and 'on' state) over 26 weeks post-implant 1 compared with the baseline scores
Modified Hoehn and Yahr stages over 26 weeks post-implant 1 compared with the baseline stages
Scores measured by the Unified Dyskinesia Rating Scale (UDysRS Parts I, II, III, IV - Parts III and IV will be performed in the 'off' and 'on' state) over 26 weeks post-implant 1 compared with the baseline scores
Times for hand-arm movement between 2 points (tapping test) in accordance with the CAPSIT-PD protocol (Defer et al. 1999) over 26 weeks post-implant 1 compared with the baseline times
Scores measured by the modified walking test in accordance with the CAPSIT-PD protocol (Defer et al. 1999) (walking 4.5m back and forth instead of 7m back and forth) over 26 weeks post-implant 1 compared with the baseline scores
Scores measured by the Parkinson's Disease Questionnaire (PDQ-39) over 26 weeks post-implant 1 compared with the baseline scores
Scores measured by neuropsychological tests at 26 weeks post-implant 1 compared with the baseline scores
TESTS USED National Adult Reading Test Speed and Capacity of Language Processing Test Boston Naming Test Trail Making Test A Trail Making Test B WMS IV Logical Memory I WMS IV Logical Memory II RAVLT List Learning RAVLT Short Delay Recall RAVLT Long Delay Recall Rey Complex Figure Copy Rey Complex Figure Delayed Recall WAIS IV Digit Span WAIS IV Matrix Reasoning WAIS IV Symbol Search WAIS IV Coding DKEFS Word Fluency DKEFS Category Fluency DKEFS Category Switching DKEFS Colour Naming DKEFS Word Reading DKEFS Inhibition DKEFS Inhibition/switching Mini Mental State Examination Montreal Cognitive Assessment HADS Anxiety HADS Depression
Psychiatric assessment at 26 weeks post-implant 1 compared with the baseline psychiatric assessment

Full Information

First Posted
November 18, 2012
Last Updated
June 7, 2020
Sponsor
Living Cell Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT01734733
Brief Title
Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease
Official Title
A Phase I/IIa, Open-label Investigation of the Safety and Clinical Effects of NTCELL [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
July 12, 2013 (Actual)
Primary Completion Date
June 4, 2015 (Actual)
Study Completion Date
June 4, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Living Cell Technologies

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To assess the safety of xenotransplantation of NTCELL [immunoprotected (alginate-encapsulated) choroid plexus cells] in patients with Parkinson's disease, assessed over the duration of the study, by monitoring the occurrence of adverse events and serious adverse events, including clinical and laboratory evidence of xenogeneic infection in transplant recipients and their partners/close contacts. Subsequent safety follow-up will include lifelong monitoring for clinical and laboratory evidence of xenogeneic infection. To assess the clinical effects of NTCELL [immunoprotected (alginate-encapsulated) choroid plexus cells] in patients with Parkinson's disease. This will be quantified by testing the secondary endpoints of the trial as described below (see Endpoints/Outcome Measures).
Detailed Description
Parkinson's disease is characterized by widespread neural degeneration, particularly in the substantia nigra and its projections to the basal ganglia. Current therapy for Parkinson's disease is purely symptomatic. There is a pressing need for a treatment that reverses or slows the degeneration of the nigrostriatal pathway. Numerous transplant-based therapies have attempted to support, repair or replace the degenerating nigrostriatal neurons. These have included the transplantation of foetal and other neuronal stem cells, gene transfers, and the implantation of devices releasing neural growth factors. All these have been shown to have some effectiveness in animal models, but have been generally disappointing in human studies. Intracranial choroid plexus cell transplantation has the potential to deliver biological neural agents for the treatment of Parkinson's disease which cannot be achieved by conventional treatment. The overall aim of delivering neural proteins and compounds over many months to the basal ganglia of the brain is to enhance neural repair currently not possible with antiparkinsonian medication or deep brain stimulation (DBS). As animal-derived tissues have to be protected from immune rejection when transplanted into humans, transplants are usually accompanied by immunosuppressive therapy. However, porcine choroid plexus cells are preferably implanted without the use of immunosuppressive drugs which cause significant morbidity. To protect them from immune rejection, the cells can be encapsulated in alginate microcapsules which permit the inward passage of nutrients and the outward passage of biologic neural proteins and compounds normally secreted by choroid plexus cells. Alginate-encapsulated porcine choroid plexus cells implanted into the brain without immunosuppressive drugs have survived rejection for many months in animal studies. NTCELL comprises neonatal porcine choroid plexus cells encapsulated in alginate microcapsules. NTCELL has been safely implanted in rats, and non-human primates. Following NTCELL implants, animals with chemically-induced Parkinson's-like lesions showed improvement of functional neurological motor abnormalities that was associated with histologic changes consistent with amelioration of the lesion. The initial dose for intracranial implantation of the current NTCELL preparation for the treatment of Parkinson's disease in humans is based on the effective dose in a non-human primate (rhesus monkey) model. Parkinson's disease patients will be followed up for 26 weeks after receiving an implantation of NTCELL administered into the putamen of the corpus striatum on the side contralateral to the greatest clinical deficit. Based upon the data obtained during the 26-week follow-up period a decision will be made as to whether the patient will receive: an implantation of a second dose of NTCELL unilateral DBS bilateral DBS no further intervention The data will be reviewed by the investigators and the Data Safety Monitoring Board (DSMB), the data will consist of clinical outcomes and clinimetric data, an MRI scan, PET scanning, and adverse events. Patients will be followed up for a further 48 weeks if there is no further intervention, however if it is decided that either DBS or implantation of a second dose of NTCELL occurs then the frequency of follow-up will be the subject of a protocol amendment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease
Keywords
Parkinson's Disease, Xenotransplantation, choroid plexus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NTCELL
Arm Type
Experimental
Arm Description
NTCELL 40 microcapsules (+/- 20%) The NTCELL microcapsules are drawn up into a catheter system and introduced intracranially by stereotactic insertion into the brain under guidance by neuroimaging.
Intervention Type
Other
Intervention Name(s)
NTCELL
Primary Outcome Measure Information:
Title
the safety of xenotransplantation of NTCELL
Description
measured by the incidence of adverse events, clinical laboratory tests (including xenogeneic viral analysis), physical examination, review by infectious disease physician
Time Frame
26 weeks
Secondary Outcome Measure Information:
Title
Brain metabolism as demonstrated on PET with [18F]-fluorodopa measured at 26 weeks post-implant 1 compared with baseline
Time Frame
26 weeks
Title
Brain metabolism as demonstrated on PET with [11C]-tetrabenazine measured at 26 weeks post-implant 1 compared with baseline
Time Frame
26 weeks
Title
Scores measured by the Unified Parkinson's Disease Rating Scale (UPDRS Parts I, II, III, IV - Parts II and III will be performed in the 'off' and 'on' state) over 26 weeks post-implant 1 compared with the baseline scores
Time Frame
26 weeks
Title
Modified Hoehn and Yahr stages over 26 weeks post-implant 1 compared with the baseline stages
Time Frame
26 weeks
Title
Scores measured by the Unified Dyskinesia Rating Scale (UDysRS Parts I, II, III, IV - Parts III and IV will be performed in the 'off' and 'on' state) over 26 weeks post-implant 1 compared with the baseline scores
Time Frame
26 weeks
Title
Times for hand-arm movement between 2 points (tapping test) in accordance with the CAPSIT-PD protocol (Defer et al. 1999) over 26 weeks post-implant 1 compared with the baseline times
Time Frame
26 weeks
Title
Scores measured by the modified walking test in accordance with the CAPSIT-PD protocol (Defer et al. 1999) (walking 4.5m back and forth instead of 7m back and forth) over 26 weeks post-implant 1 compared with the baseline scores
Time Frame
26 weeks
Title
Scores measured by the Parkinson's Disease Questionnaire (PDQ-39) over 26 weeks post-implant 1 compared with the baseline scores
Time Frame
26 weeks
Title
Scores measured by neuropsychological tests at 26 weeks post-implant 1 compared with the baseline scores
Description
TESTS USED National Adult Reading Test Speed and Capacity of Language Processing Test Boston Naming Test Trail Making Test A Trail Making Test B WMS IV Logical Memory I WMS IV Logical Memory II RAVLT List Learning RAVLT Short Delay Recall RAVLT Long Delay Recall Rey Complex Figure Copy Rey Complex Figure Delayed Recall WAIS IV Digit Span WAIS IV Matrix Reasoning WAIS IV Symbol Search WAIS IV Coding DKEFS Word Fluency DKEFS Category Fluency DKEFS Category Switching DKEFS Colour Naming DKEFS Word Reading DKEFS Inhibition DKEFS Inhibition/switching Mini Mental State Examination Montreal Cognitive Assessment HADS Anxiety HADS Depression
Time Frame
26 weeks
Title
Psychiatric assessment at 26 weeks post-implant 1 compared with the baseline psychiatric assessment
Time Frame
26 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: To be assessed at the Week -10 to -4 Visit Adults (males or females) in the age range 40 to 70 years Diagnosis of Parkinson's disease (minimum duration of 5 years) in accordance with the London Brain Bank criteria Patients diagnosed with idiopathic Parkinson's disease Stable medication for Parkinson's for at least 1 month Patients with advanced and fluctuating Parkinson's disease who have met the criteria for DBS and who have been accepted for DBS at Auckland City Hospital. These criteria include exhaustion of available medication treatments for Parkinson's disease, normal brain MRI, intact cognitive, psychological and psychiatric function, appropriate carer support, and competence and willingness to consent to the placement of deep brain probes If female, no childbearing capability (those who are more than 2 years postmenopausal or have undergone voluntary sterilisation can be considered for enrolment) Provision of written informed consent. Patients will be required to agree to comply with all tests and visits specified in the protocol, and they (and their partners/close contacts) will also be required to consent to long-term microbiological monitoring, which is an integral part of the study. Exclusion Criteria: To be assessed at the Week -10 to -4 Visit Note: the criteria for acceptance for DBS would exclude patients with comorbidities that normally would exclude them from similar studies, including uncontrolled depression, dementia, focal neurological deficits, or secondary parkinsonism. Specific exclusion criteria in this category are: Any history of central nervous system infection Significant dementia as determined by neuropsychological assessment Focal neurological defects Evidence of significant medical or psychiatric disorders Secondary parkinsonism Severe autonomic symptoms Atypical Parkinson's disease History of substance abuse Body mass index (BMI) ≥30 kg/m2 or ≤20 kg/m2 Serious comorbid conditions that are likely to affect participation in the study, including: Previous coronary heart disease manifesting as non-ST elevation myocardial infarction (NSTEMI), Q-wave infarction or unstable angina; coronary artery bypass graft (CABG); or percutaneous angioplasty Previous cerebrovascular disease manifesting as transient ischaemic attacks (TIAs) or stroke Peripheral vascular disease with foot ulcer and/or previous amputation History of New York Heart Association (NYHA) class II, III or IV congestive heart failure (CHF) and/or chronic atrial fibrillation Chronic obstructive pulmonary disease (COPD) or asthma with previous hospitalisation for decompensation; a requirement for mechanical ventilation at any stage; or long-term treatment with oral corticosteroids Liver disease with abnormal liver function tests defined as serum bilirubin ≥20 µmol/L, and/or ALT ≥100 U/L, and/or GGT ≥100 U/L, and/or albumin < 35 g/L Haematological disorders, including haemoglobin ≤110 g/L or platelet count < 80 x 109/L Kidney disease, defined as serum creatinine > 130 μmol/L in men and > 110 μmol/L in women and/or haematuria and/or active urinary sediment or casts Peptic ulcer disease and/or history of previous gastrointestinal bleeding Malignancy other than basal cell carcinoma History of epilepsy Untreated hypothyroidism Known adrenal insufficiency Other exclusion criteria: Past history of brain surgery for Parkinson's disease Poor candidate for any surgery HIV antibody and/or risk factors for HIV infection Positive hepatitis C antibody, positive hepatitis B surface antigen, and hepatitis B core antibody Current administration of immunosuppressive medications (e.g. cyclosporin, tacrolimus, sirolimus, mycophenolate mofetil, muromonab-CD3, daclizumab, basiliximab, antithymocyte globulin, interferons) for other disease conditions Inability to travel on aeroplane to Vancouver (for PET scan) Any other condition that, in the opinion of the Investigator, may interfere with adherence to the study protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Barry Snow, MBChB
Organizational Affiliation
Auckland City Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Auckland City Hospital
City
Auckland
Country
New Zealand

12. IPD Sharing Statement

Links:
URL
http://www.lctglobal.com/
Description
Related Info

Learn more about this trial

Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease

We'll reach out to this number within 24 hrs